Oral versus Intravenous Antibiotics for Bone and Joint Infection
Cette étude a été identifiée comme étant potentiellement à fort impact.
L'indicateur High Impact de l'ENP, basé sur l'IA, estime l'influence qu'un article est susceptible d'avoir en intégrant des signaux provenant à la fois de la revue dans laquelle il est publié et du contenu scientifique de l'article lui-même.
Développé à l'aide d'un traitement du langage naturel de pointe, le modèle High Impact de l'ENP prédit avec plus de précision les futures citations d'une étude que le seul facteur d'impact de la revue.
Cela permet d'identifier plus tôt les recherches cliniquement significatives et aide les lecteurs à se concentrer sur les articles les plus susceptibles de façonner la pratique future.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(1):10 N Engl J Med. 2019 Jan 31;380(5): 425-436.Qu'est-ce que cela signifie pour ma pratique ?
The results of this study suggest that oral antibiotics are non-inferior to intravenous antibiotics for the management of bone and joint infection, as measured by treatment failure. Moreover, oral antibiotics are associated with a shorter length of stay and fewer complications compared to intravenous treatment. This study was limited by the open label design and potential differences in follow-on treatment. This study challenges the widely accepted standard use of intravenous antibiotics for bone/joint infection.
Résumé de l'étude
1054 patients being treated for bone or joint infection at 26 UK centers were randomized in this non-inferiority trial to receive 6 weeks of oral antibiotic therapy (n=527) or 6 weeks of intravenous antibiotic therapy (n=527). The primary outcome of interest was the rate of definite treatment failure. Secondary outcomes of interest included the rate of treatment discontinuation, catheter complications, diarrhea caused by C.difficile, serious adverse events, length of hospitalization, and patient-reported outcomes (Oxford Hip and Knee Scores [OHS; OKS]; EuroQual-5Dimension scores [EQ-5D]). Outcomes were assessed at 6 weeks, 4 months, and 1 year follow-up. Oral antibiotics were found to be non-inferior to intravenous antibiotics with regards to the risk of definitive treatment failure. The incidence of early discontinuation of treatment and catheter complications, and length of hospitalization were significantly higher in the intravenous group, however, no differences in the incidence of diarrhea or serious adverse events were observed between the two groups. EQ-5D scores and OHS scores were not significantly different between groups at 4 months and 1 year post-treatment, however, OKS scores were better in the oral group at both time points.
Pourquoi cette étude était-elle nécessaire aujourd'hui ?
Patients with bone and joint infection require prolonged antibiotic treatment, which is frequently delivered intravenously. However, the use of intravenous antibiotics has been associated with additional complications and higher costs vs. oral antibiotics. Therefore, it is of interest to determine whether oral antibiotics can provide an non-inferior management of bone and joint infection.
Quelle était la principale question de recherche ?
In patients with acute or chronic bone/joint infection, is oral antibiotic therapy non-inferior to intravenous antibiotic therapy with respect to treatment success, within 1 year post-randomization?
AVIS DE NON-RESPONSABILITÉ
Le contenu de cette page est fourni à titre d'information uniquement et n'est pas destiné à remplacer un avis médical, un diagnostic ou un traitement professionnel. Si vous avez besoin d'un traitement médical, demandez toujours l'avis de votre médecin ou rendez-vous au service des urgences le plus proche. Les opinions, croyances et points de vue exprimés par les individus sur le contenu de cette page ne reflètent pas les opinions, croyances et points de vue d'OrthoEvidence.
0 de 4 articles mensuels GRATUITS débloqués
